Advances unveiled at the Advances in Genome Biology and Technology (AGBT) meeting signaled a renewed scramble for high‑throughput genomics: Element Biosciences, Ultima Genomics, Roche (Axelios 1), Complete Genomics and others showcased platforms aimed at delivering billions of reads at sharply lower per‑genome costs. Presentations and vendor roadmaps suggest increasing capacity options beyond Illumina’s NovaSeq X. At the same time, Oxford Nanopore reported 22% revenue growth for 2025 while executing a strategic restructuring to focus on high‑priority products and cut costs. The firm trimmed headcount and narrowed its portfolio while keeping investment in production to meet demand. The combined signals point to a market moving toward more supplier diversity at the clinical scale, with implications for sequencing costs, clinical genomics capacity and downstream applications such as minimal residual disease testing and population sequencing.